Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
famotidine calcium carbonate magnesium hydroxide · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | Famotidine/antacid combination tablet with water |
| B | EXPERIMENTAL | Famotidine/Antacid EZ Chew tablet without water |
| C | EXPERIMENTAL | Famotidine/Antacid EZ Chew tablet with water |
| Name | Type | Description |
|---|---|---|
| famotidine (+) calcium carbonate (+) magnesium hydroxide tablet | DRUG | A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods |
| Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water | DRUG | A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods |
| Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water | DRUG | A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods |
Inclusion Criteria: * Female subject is not pregnant or lactating, Females of childbearing potential must use reliable means of contraception during the course of the study * Subject is in good health * Subject is able to abstain from smoking during the 24-hour periods before and during each treatm...
Famotidine calcium carbonate magnesium hydroxide is a small molecule combination product being developed by Johnson & Johnson for heartburn. It combines famotidine, an HRH2 antagonist, with the antacids calcium carbonate and magnesium hydroxide in a single tablet. It is in Phase 1 clinical development.
Famotidine calcium carbonate magnesium hydroxide is being developed for heartburn. The combination pairs famotidine, an HRH2 antagonist, with calcium carbonate and magnesium hydroxide, which are antacids. Johnson & Johnson is developing the product, and its clinical work to date has been in Phase 1.
Famotidine calcium carbonate magnesium hydroxide contains famotidine, which targets HRH2, the histamine H2 receptor, as an antagonist. The calcium carbonate and magnesium hydroxide components act as antacids. The combination is designed to address heartburn through both H2 receptor blockade and antacid activity.
Johnson & Johnson, which trades under the ticker JNJ, is the developer of famotidine calcium carbonate magnesium hydroxide. The company is studying the combination tablet for heartburn. It is a small molecule product in Phase 1 development.
Famotidine calcium carbonate magnesium hydroxide is in Phase 1 development. It is an investigational combination product and is not approved. One Phase 1 trial has been completed, and no trials are currently active.
Famotidine calcium carbonate magnesium hydroxide has been studied in one completed Phase 1 trial, NCT00944671, titled a study to assess the bioequivalence of famotidine/antacid combination tablets compared to famotidine/antacid EZ chew tablets. That randomized, active-controlled trial enrolled 24 healthy volunteers aged 18 years and older and included both sexes.